<DOC>
	<DOCNO>NCT01310738</DOCNO>
	<brief_summary>This study aim compare efficacy safety medication currently use Brazil treatment visceral leishmaniasis . The investigator compare effect meglumine antimoniate , two formulation amphotericin B : deoxycholate liposomal , combination meglumine plus liposomal amphotericin B formulation . The study design demonstrate difference efficacy measure cure rate six month treatment safety profile base adverse event rate observe intervention .</brief_summary>
	<brief_title>Efficacy Safety Study Drugs Treatment Visceral Leishmaniasis Brazil</brief_title>
	<detailed_description>Visceral leishmaniasis relevant public health problem Brazil approximately 3500 case register every year . Eight percent lethality rate observe past decade spite free charge availability antileishmanial drug supply public health system . The present study design phase IV , multicentric , open label , active control clinical trial target visceral leishmaniasis adult pediatric case . The current drug approve visceral leishmaniasis treatment Brazil compare four treatment group : meglumine antimoniate , amphotericin B deoxycholate , liposomal amphotericin B combination single dose liposomal amphotericin B plus meglumine antimoniate . Meglumine antimoniate treat patient constitute active control group . Drugs compare base cure rate observe six month follow-up . The study arm submit treatment Amphotericin B deoxycholate suspend September 2012 .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B , deoxycholate drug combination</mesh_term>
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>patient visceral leishmaniasis characterize fever plus hepatomegaly splenomegaly least one positive result follow laboratory test : direct observation leishmania amastigotes bone marrow smear leishmania vitro culture bone marrow aspirate leishmania kDNA amplification PCR bone marrow peripheral blood sample rK39 immunochromatographic rapid test perform serum sample pregnancy HIV infection chronic diseases diabetes mellitus , kidney , liver cardiac disease , schistosomiasis , malaria tuberculosis immune disorder use drug interferes immune response treatment drug increase risk toxicity associate study drug exposure antileishmanial drug past six month I.V . drug user episodes visceral leishmaniasis relapse hypersensibility study drug difficulty accomplish followup schedule follow clinical sign laboratory abnormality : hepatic encephalopathy , generalize edema , toxemic individual , severe malnutrition , jaundice , abnormal serum creatinine , bilirubin , INR &gt; 2,0 , platelet count &lt; 20000/mm3</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Visceral leishmaniasis</keyword>
	<keyword>Leishmania infantum</keyword>
	<keyword>Leishmania chagasi</keyword>
</DOC>